7570-49-2

Usage

Uses

Used in Pharmaceutical Industry:
5-AMINO-2-METHYLINDOLE is used as a reactant for the preparation of cytotoxic and antimitotic agents, which are crucial in the development of treatments for cancer and other proliferative disorders.
Used in Antimicrobial Applications:
In the field of antimicrobial research, 5-AMINO-2-METHYLINDOLE is utilized as a reactant for the synthesis of potential antimicrobial aminoketones, which can be used to combat bacterial and fungal infections.
Used in Neuropharmacology:
5-AMINO-2-METHYLINDOLE serves as a reactant in the preparation of inhibitors of monoamine oxidase (MAO), which are essential in the treatment of various psychiatric and neurological disorders.
Used in Cellular Signaling Research:
5-AMINO-2-METHYLINDOLE is used as a reactant for the synthesis of protein kinase C theta (PKCθ) inhibitors, which play a significant role in modulating cellular signaling pathways and have potential applications in the treatment of autoimmune diseases and cancers.
Used in Hematology:
5-AMINO-2-METHYLINDOLE is employed as a reactant in the preparation of Factor Xa inhibitors, which are vital in the development of anticoagulant drugs for the prevention and treatment of blood clot-related disorders.
Used in Angiogenesis Inhibition:
In the field of oncology, 5-AMINO-2-METHYLINDOLE is used as a reactant for the synthesis of inhibitors of vascular endothelial growth factor type 2 (VEGFR-2), which are crucial in the development of anti-angiogenic therapies to prevent the growth of new blood vessels in tumors.
Used in Natural Product Synthesis:
5-AMINO-2-METHYLINDOLE is utilized as a reactant in the preparation of demethylasterriquinone B1 receptor ligands, which are important in the study and development of novel bioactive natural products with potential applications in various therapeutic areas.
Used in Chemical Synthesis:
5-AMINO-2-METHYLINDOLE is a valuable reactant in the synthesis of a wide range of chemical compounds, making it an essential component in various chemical and pharmaceutical processes.

InChI:InChI=1/C9H10N2/c1-6-4-7-5-8(10)2-3-9(7)11-6/h2-5,11H,10H2,1H3

Upstream product

• 7570-47-0 5-nitro-2-methylindole 
• 500730-27-8 N'-(3-acetyl-2-methyl-indol-5-yl)-N,N-dimethyl-sulfamide 
• 500730-25-6 N',N',N''',N'''-tetramethyl-N,N''-[(1-acetyl-2-oxo-propyl)-p-phenylene]-bis-sulfamide 
• 115210-54-3 2-methyl-5-nitroindoline 
• 95-20-5 2-methyl-1H-indole 
• 438187-35-0 2-iodo-N¹,N⁴-di[(E)-phenylmethylidene]-benzene-1,4-diamine 
• 69951-01-5 2-iodo-1,4-phenylenediamine 
• 6293-83-0 2-iodo-4-nitrophenylamine 
• 438187-37-2 2-(2-methoxy-2-propenyl)-N¹,N⁴-di[(E)-phenylmethylidene]-benzene-1,4-diamine 

Downstream Products

• 132515-37-8 N-(2-methyl-1H-indol-5-yl)benzamide 
• 686747-17-1 3-chloro-2-methyl-N-(2-methyl-1H-indol-5-yl)benzenesulphonamide 
• 865375-68-4 2,4-dichloro-N-(2-methyl-1H-indol-5-yl)-benzenesulfonamide 
• 869188-27-2 4-fluoro-N-(2-methyl-1H-indol-5-yl)-3-trifluoromethyl-benzamide 
• 225382-63-8 [2-(3-Methyl-3H-imidazol-4-yl)-thieno[3,2-b]pyridin-7-yl]-(2-methyl-1H-indol-5-yl)-amine 
• 225382-64-9 2-{1-Methyl-5-[7-(2-methyl-1H-indol-5-ylamino)-thieno[3,2-b]pyridin-2-yl]-1H-imidazol-2-yl}-propan-2-ol 
• 225382-65-0 [2-(1-Methyl-1H-imidazol-2-yl)-thieno[3,2-b]pyridin-7-yl]-(2-methyl-1H-indol-5-yl)-amine 
• 477875-08-4 {2-[5-(4-Methoxy-phenyl)-oxazol-2-yl]-thieno[3,2-b]pyridin-7-yl}-(2-methyl-1H-indol-5-yl)-amine 
• 1160918-74-0 4-[(2-methyl-1H-indol-5-yl)amino]-5-[(E)-2-phenylvinyl]nicotinonitrile 
• 1181814-65-2 5-(2-aminophenyl)-[1,3,4]oxadiazole-2-carboxylic acid (2-methyl-1H-indol-5-yl)amide 
• 1207835-09-3 2-(2-methyl-1H-5-indolylamino)benzoic acid 
• 1207835-10-6 5-methoxy-2-(2-methyl-1H-5-indolylamino)benzoic acid 
• 628709-30-8 C₁₇H₁₄N₄O 
• 1253057-39-4 (2E)-N-(2-methyl-1H-indol-5-yl)-3-phenylprop-2-enamide 

Relevant academic research and scientific papers

Textile-supported silver nanoparticles as a highly efficient and recyclable heterogeneous catalyst for nitroaromatic reduction at room temperature

A novel textile-based nanosilver catalyst was prepared with a facile synthetic method. The textile-supported nanosilver (TsNS) proved to be an excellent heterogeneous catalyst for the reduction of nitroaromatics with a broad substrate scope. It can be recycled for up to 6 times without significantly compromising its catalytic efficacy. The TsNS catalyst was developed into a column reactor, demonstrating its practical application with the advantages of low cost, ease of operation and large scale synthesis capabilities. Scanning electron microscopy (SEM) showed that there were few changes to the catalyst's surface after the reaction. Besides, inductively coupled plasma (ICP) analysis showed that few silver particles leaked, and the interactions between the nitro groups of the nitroaromatics and the nanosilver particles were characterized by X-ray photoelectron spectroscopy (XPS), which lead to the proposal of a four-step mechanism for the reduction reaction.

Palladium nanoparticles stabilized by aqueous vesicles self-assembled from a PEGylated surfactant ionic liquid for the chemoselective reduction of nitroarenes

Vesicles self-assembled from an aqueous PEGylated surfactant ionic liquid solution can be applied for stabilizing palladium nanoparticles, which prove to be an efficient catalytic system for chemoselective hydrogen transfer of nitroarenes using hydrazine hydrate as a hydrogen source. The particle sizes of vesicles are decreased with the increase of ionic liquid's concentrations and relatively small particle sizes are beneficial to the reduction. Moreover, the aqueous catalytic system still stays in reactor by simple extraction, and is reused without further treatment.

Synthesis and evaluation of indole-based chalcones as inducers of methuosis, a novel type of nonapoptotic cell death

Methuosis is a novel caspase-independent form of cell death in which massive accumulation of vacuoles derived from macropinosomes ultimately causes cells to detach from the substratum and rupture. We recently described a chalcone-like compound, 3-(2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propen-1- one (i.e., MIPP), which can induce methuosis in glioblastoma and other types of cancer cells. Herein, we describe the synthesis and structure-activity relationships of a directed library of related compounds, providing insights into the contributions of the two aryl ring systems and highlighting a potent derivative, 3-(5-methoxy, 2-methyl-1H-indol-3-yl)-1-(4-pyridinyl)-2-propen-1-one (i.e., MOMIPP) that can induce methuosis at low micromolar concentrations. We have also generated biologically active azide derivatives that may be useful for future studies aimed at identifying the protein targets of MOMIPP by photoaffinity labeling techniques. The potential significance of these studies is underscored by the finding that MOMIPP effectively reduces the growth and viability of Temozolomide-resistant glioblastoma and doxorubicin-resistant breast cancer cells. Thus, it may serve as a prototype for drugs that could be used to trigger death by methuosis in cancers that are resistant to conventional forms of cell death (e.g., apoptosis).

Preparation of Polyfunctional Heterocycles Using Highly Functionalized Aminated Arylmagnesium Reagents as Versatile Scaffolds

(Equation Presented) Functionalized Grignard reagents, derived from readily available o-iodoaniline derivatives and obtained via a straightforward iodine-magnesium exchange, can be used to prepare a wide range of polyfunctional indoles, quinolines, and quinazolinones.

Thienopyrimidine and thienopyridine derivatives useful as anticancer agents

The invention relates to compounds of the formulas 1 and 2 and to pharmaceutically acceptable salts and hydrates thereof, wherein X1, R1, R2and R11are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formulas 1 and 2 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formulas 1 and 2.

5-SUBSTITUTED-3-(1,2,3,6-TETRAHYDROPYRIDIN-4-YL)-AND 3-(PIPERIDIN-4-YL)-1H-INDOLES: NEW 5-HT1F AGONISTS

This invention provides novel 5-HT 1F agonists of Formula I STR1 where A--B, R, R 1 and X are as defined in the specification, which are useful for the treatment of migraine and associated disorders.

Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis

This invention provides methods for the treatment or amelioration of the symptoms of the common cold or allergic rhinitis which comprises administering to a mammal in need thereof a serotonin 5-HT1F agonist.

Use of serotonin 5-HT1F agonists for the prevention of migraine

This invention provides methods for the prevention of migraine which comprises administering to a mammal in need thereof a serotonin 5-HT1F agonist.